In the Boardroom
Refine Search
Pharmaceutical
US pharma major Eli Lilly has announced that Joshua Smiley will be appointed to the post of senior vice president, finance, and treasurer effective October 1. 11 August 2016
Pharmaceutical
A series of changes to the executive management team have been announced by Canada-based Valeant Pharmaceuticals and its new chief executive Joe Papa. 9 August 2016
Biotechnology
Specialty drug firm Sygnis Pharma AG has appointed Heikki Lanckriet as its new chief executive and chief scientific officer (CSO). 8 August 2016
Biotechnology
Privately-held UK biotech Chronos Therapeutics has appointed experienced pharma duo Fraser Murray and Timothy Schulz-Utermoehl as vice presidents of pre-clinical development. 4 August 2016
Pharmaceutical
US pharma major Eli Lilly is to have an new president and chief executive effective next year, as incumbent John Lechleiter is to retire at the end of 2016, the company has announced. 27 July 2016
Pharmaceutical
Fouad Namouni has been appointed oncology development head at US pharma major Bristol-Myers Squibb, effective July 25, 2016. 26 July 2016
Biotechnology
George Scangos is to step down as the chief executive of US biotech major Biogen, it was announced on Thursday, when the company also revealed results for 2016’s second quarter which exceeded analysts’ expectations. 21 July 2016
Generics
Ireland-incorporated Perrigo has announced that Douglas Boothe, the general manager of its Rx Pharmaceuticals segment, is leaving the company. 21 July 2016
Pharmaceutical
The pharmaceutical industry’s use of directors from outside the sector has fallen from 40% to 26% in the last five years, research from executive search firm DHR International shows. 12 July 2016
Pharmaceutical
French pharma company Ipsen has appointed David Meek as chief executive, effective July 18, 2016. 11 July 2016
article
Taro Pharmaceutical Industries announced today that its chief executive, Kalyanasundaram (Kal) Sundaram, has informed Taro’s board of directors of his intention to step down as CEO by the end of the current calendar year. 7 July 2016
Biotechnology
China-based biopharma firm CStone Pharmaceuticals says it has closed its Series A round of $150 million dollars financing (about 975 million renminbi). 4 July 2016
Pharmaceutical
USA-based generic pharmaceutical company G & W Laboratories has announced the appointment of Jay Galeota to the position of president and chief operating officer. 30 June 2016
Biotechnology
Edward Jensen, the new chief operating officer at US-based Blueprint Bio, has described his excitement at being part of "arguably the most groundbreaking" venture in health care. 27 June 2016
Pharmaceutical
Aimmune Therapeutics, a US-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its new chief medical officer. 23 June 2016
Pharmaceutical
Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly-created position, at US pharma major Bristol-Myers Squibb, effective June 21, 2016. 22 June 2016
Biotechnology
A former heavyweight at US health care giant Johnson & Johnson has been named in a key position with Biogen to lead the biotech company’s growth in development and manufacturing. 22 June 2016
Pharmaceutical
Shares in British drugmaker GlaxoSmithKline (LON: GSK) fell some 2.35% in Tuesday trading, on the news that the company's vaccines boss, Moncef Slauoi, is to retire in June 2017. 15 June 2016
Pharmaceutical
Shareholders of German family-owned pharma major Boehringer Ingelheim have decided to appoint Simone Menne to the firm’s board of managing directors with effect from September 1, 2016. 10 June 2016
Pharmaceutical
The US District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen Therapeutics and Japan’s Takeda Pharmaceutical against Andrx and Actavis (now Allergan) companies. 10 June 2016
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze